TZIELD: cost and payments to doctors
What Medicare Part D paid pharmacies for TZIELD, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Sanofi-aventis U.S. LLC?
Sanofi-aventis U.S. LLC reported the most payments naming TZIELD. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $9.5M
- Providers
- 26,148
- Transactions
- 68,608
- Average per transaction
- $139
The per-transaction average — $139 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 26,148 providers the average total is $364, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi-aventis U.S. LLC | $8,855,550 | 92.9% |
| Sanofi US Services Inc. | $400,926 | 4.2% |
| Sanofi | $273,841 | 2.9% |
| Sanofi Pasteur Inc. | $27 | 0.0% |
Other products from Sanofi-aventis U.S. LLC
The company that reported the most payments naming TZIELD also reports against these.
- SOLIQUA 100/33$10,474,032
- TOUJEO$6,172,887
- DUPIXENT$4,377,310
- MULTAQ$3,603,705
- PRALUENT$3,219,961
- THYMOGLOBULIN$2,596,054
- REZUROCK$1,969,127
- NO PRODUCT DISCUSSED$1,624,453
- AUBAGIO$523,272
- DISEASE STATE$471,320